Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Safety Information

SML2591

Sigma-Aldrich

SCH-39166 hydrobromide

≥98% (HPLC)

Synonym(s):

(-)-trans-6,7,7a,8,9,13b-Hexahydro-3-chloro-2-hydroxy-N-methyl- 5H-benzo[d]naptho-(2,1-b)azepine hydrobromide, (6aS,13bR)-11-Chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-5H-benzo[d]naphth[2,1-b]azepin-12-ol hydrobromide, (6aS-trans)-11-Chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-5H-Benzo[d]naphth[2,1-b]azepin-12-ol hydrobromide, Ecopipam hydrobromide, PSYRX 101 hydrobromide, PSYRX-101 hydrobromide, PSYRX101 hydrobromide, SCH 39166 hydrobromide, SCH39166 hydrobromide

Sign Into View Organizational & Contract Pricing

Select a Size

5 MG
¥15,500
25 MG
¥62,400

¥15,500

Check Cart for Availability
Request a Bulk Order
All Photos(1)

Select a Size

Change View
5 MG
¥15,500
25 MG
¥62,400

About This Item

Empirical Formula (Hill Notation):
C19H20ClNO·HBr
CAS Number:
2587360-22-1
Molecular Weight:
394.73
MDL number:
MFCD08703109
UNSPSC Code:
12352200
NACRES:
NA.77

¥15,500

Check Cart for Availability
Request a Bulk Order

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Biochem/physiol Actions

High-affinity D1/D5 subtype-selective dopamine receptor antagonist with in vitro and in vivo efficacy.
SCH-39166 (ecopipam) is a high-affinity D1/D5 subtype-selective dopamine receptor antagonist (Ki = 1.2 nM/D1, 2.0 nM/D5, 980 nM/D2, 5.52 μM/D4, 80 nM/5-HT, 731 nM/α2a). SCH-39166 is widely employed both in cultures and in animal studies in vivo.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H336

Hazard Classifications

STOT SE 3

Target Organs

Central nervous system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

SML2591-25MG:
SML2591-5MG:
SML2591-BULK:
SML2591-VAR:

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000424152
0000424147
0000424147
0000424152
0000399475

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Brendan D Hare et al.
Nature communications, 10(1), 223-223 (2019-01-16)
Impaired function in the medial prefrontal cortex (mPFC) contributes to depression, and the therapeutic response produced by novel rapid-acting antidepressants such as ketamine are mediated by mPFC activity. The mPFC contains multiple types of pyramidal cells, but it is unclear
Yang Yang et al.
Molecular psychiatry (2018-12-12)
Dopamine D1 agonists enhance cognition, but the role of different signaling pathways (e.g., cAMP or β-arrestin) is unclear. The current study compared 2-methyldihydrexidine and CY208,243, drugs with different degrees of both D1 intrinsic activity and functional selectivity. 2-Methyldihydrexidine is a
Meera E Modi et al.
Frontiers in molecular neuroscience, 11, 107-107 (2018-07-05)
Mutations in the SHANK family of genes have been consistently identified in genetic and genomic screens of autism spectrum disorder (ASD). The functional overlap of SHANK with several other ASD-associated genes suggests synaptic dysfunction as a convergent mechanism of pathophysiology
Yunjin Lee et al.
Experimental neurobiology, 27(6), 539-549 (2019-01-15)
Autism spectrum disorder (ASD) is a heterogeneous group of neurobehavioral disorders characterized by the two core domains of behavioral deficits, including sociability deficits and stereotyped repetitive behaviors. It is not clear whether the core symptoms of ASD are produced by
Martin Clark et al.
Frontiers in cellular neuroscience, 12, 260-260 (2018-09-07)
The ventral pallidum (VP) is crucially involved in reward processing. Dopaminergic afferents reach the VP from the ventral tegmental area (VTA). Recent in vivo studies suggest dopamine application increase the firing in the VP. However, little is known about the
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service